
JasonDoiy
- Merck (MRK) has abandoned development of the oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib after a Data Monitoring Committee evaluating a phase 3 trial suggested the benefits of the therapy may not outweigh the risks.
- The pharma made its
